iRhythm Announces Approval of $200 Million Share Repurchase Program
Globe Newswire•11/11/2026•16:05 ET
0
Key Highlights
- ➤iRhythm authorizes up to $200 million for common-stock repurchases
- ➤Repurchases may use open-market, negotiated, accelerated, or other transactions
- ➤Program funding expected from existing cash and ongoing operating cash flow
- ➤VitalConnect acquisition cited as a significant new growth opportunity
SAN FRANCISCO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company’s outstanding common stock.
The approval reflects iRhythm’s confidence in the continued strength of its core business, as well as its significant new growth opportunities from the addition of the recently acquired VitalConnect business.
Get started
Create a free account to read the full story.